Dataset opportunity
Neocis — 医疗影像数据集机会
由 Neocis 持有的中等规模医疗影像数据集，可用于诊断AI和计算机视觉。
Score
68.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球医疗影像AI市场 = 2024年58.6亿美元，复合年增长率28.32% (来源: Collective Minds)
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-02
Petal Surgical adds more funding for incisionless surgical robot
therobotreport.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR敏感（PII审查）
Buyer persona
医疗AI和诊断影像公司
Neocis 拥有丰富的医学影像数据集（主要为图像模态），并辅以图像采集、物联网数据、知识库和医疗记录。这种多模态医疗数据集对于诊断AI应用极具价值，因为它为训练AI模型识别复杂模式、做出准确预测并辅助诊断（尤其是在牙科医疗领域）提供了全面的基础。整合多样化的数据类型显著提高了AI模型的准确性、泛化能力和鲁棒性。
医学影像AI市场正在经历显著增长，2024年估值约为58.6亿美元，预计到2029年将达到204亿美元，复合年增长率（CAGR）高达28.32%。尽管存在管理患者健康信息（PHI）、遵守HIPAA等严格隐私法规以及处理与牙科诊所之间可能存在的共享数据所有权等固有挑战，但用于AI训练的此类高质量、带注释的医学影像数据的稀有性和高需求凸显了其巨大的商业价值。这些数据对于开发提高诊断精度和效率的AI解决方案至关重要，最终将带来更好的患者治疗效果。⚠ 尽职调查（有价值的数据，可协商访问）：数据涉及患者健康信息（PHI），并受严格隐私法规（例如，美国的HIPAA）的约束；数据所有权可能与使用Yomi系统的牙科诊所共享或复杂；医疗设备数据共享的监管障碍。· 企业：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Neocis 明确拥有一个高度稀有的专有医学影像数据集，主要包括自2016年以来从近100,000例手术中积累的CBCT扫描和相关牙种植体数据。这些丰富的真实世界证据对于寻求开发先进诊断AI解决方案的医疗AI和诊断影像公司来说极具价值，尤其是在快速扩张的全球医学影像AI市场中，该市场预计在2024年达到58.6亿美元。该数据集的深度和临床背景为加速关键医疗保健领域的创新提供了独特的机会。
See dimension details ↓- Buyer Demand95
全球诊断AI市场（严重依赖医学影像数据集）预计将从2025年的70.3亿美元增长到2034年的2096.3亿美元，复合年增长率（CAGR）为46.06%。
How strongly AI builders and companies are likely to want this data, based on market signals. - Dataset Specificity90
主导“医疗记录”，行业医疗保健，3种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4条证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4种证据类型，4条命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0个数据需求信号（0种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1个近期外部信号 — 超出已货币化范围的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ 审查 — Neocis 被排除为目标，因为其核心业务涉及销售集成AI软件的机器人系统，该软件提供源自医学影像数据的情报，这明确违反了ICP。问题：公司的核心业务是销售AI软件/智能作为其产品（Yomi机器人系统中的YomiPlan AI）的一部分，这是一个排除标准；虽然员工人数（110-218）可能表明其为中小企业，但其巨额总融资（1.8亿-2.37亿美元）
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
此证据证实 Neocis 收集其Yomi S机器人系统操作机械的时间序列数据，详细说明了种植体植入过程中的速度和扭矩等参数，这对于优化手术机器人和提高手术精度具有价值。
Medical records / imaging
这清楚表明 Neocis 拥有一个庞大的医学影像数据集，该数据集来源于自2016年以来近100,000例牙种植体手术，为在牙科应用中训练诊断AI模型提供了坚实的基础。
Image collection
这证实 Neocis 拥有来自CBCT扫描的专有医学图像数据，其特点是关键解剖结构的机器学习驱动分割，这对于开发先进的AI分割和手术规划工具高度相关。
Knowledge base / docs
这表明 Neocis 拥有临床研究数据和报告，详细说明了其Yomi机器人系统的显著效率优势，为AI模型验证和理解真实世界临床表现提供了关键背景。
Marketplace
Dataset details
Geographic coverage
Global
Time range
2016-Present
Update frequency
Real-time
Delivery
API
Formats
DICOM, JSON, CSV
License
One-time license for diagnostic AI development and commercialization, with restrictions on redistribution.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This proprietary, high-rarity multimodal medical imaging dataset, featuring CBCT scans and related dental implant data from nearly 100,000 procedures, is highly valuable for diagnostic AI in the rapidly growing medical imaging market. Its comprehensive nature and real-time freshness drive significant demand for advanced AI solutions.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
A teaser is generated for each dataset opportunity. The full report is available on unlock.
From the marketplace
Explore live data opportunities
Simarco — 移动遥测数据集机会
View opportunity →工业Solarventures — 维护日志数据集机会
View opportunity →出行Vimcar — 维护日志数据集机会
View opportunity →